AUTHORS
Pu Zhang, Xiangyu Pan2, Ali Cihan3, Khrystyna North4, Xiaochen Gao5, Xiao-Lu Teng6, Maxim Isaac Maron, MD, PhD7, Cynthia Castro8, Peng Li9, Farhad Forouhar10, Jeetayu Biswas11, Jahan Rahman12, Alexander Lewis13, Sebastian Carrasco14, Ming Li15, Anthony Daniyan, MD16, Robert Bradley17, Sisi Chen, PhD18, Omar Abdel-Wahab, MD19
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Weill Cornell Medicine, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Fred Hutchinson Cancer Research Center, Seattle, United States
5 Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Columbia University Irving Medical Center, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Fred Hutchinson Cancer Research Center, Seattle, United States
18 Shanghai Jiao Tong University School of Medicine, Shanghai, China
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Mutations in RNA splicing factors are common across myeloid neoplasms as well as clonal hematopoiesis. While many aberrant transcripts created in splicing factor mutant cells encode stable, altered proteins, the functional roles of these protein-coding RNA isoforms have not been systematically interrogated. Here we performed in vivo screens of hundreds of spliceosome mutation–induced isoforms in syngeneic clonal hematopoietic cells. This screen revealed enrichment of multiple mutant-induced RNA isoforms converging on downregulation of MHC class II antigen presentation. Mutations in the core splicing factor U2AF1 simultaneously promoted aberrant isoforms of the protease SPPL2A and the MHC II chaperone CD74, impairing SPPL2A-mediated CD74 cleavage, a process essential for endosomal MHC II-peptide loading and surface presentation. These mutation-induced SPPL2A and CD74 isoforms reduced killing of tumor cells by CD4+ T cells engineered to express T cell receptors to specific MHC II antigens, directly linking a mis-spliced protein isoform to the fitness and malignant progression of mutant hematopoietic clones.
To identify functional spliceosome mutation–induced isoforms, we developed an unbiased in vivo cDNA screening platform encoding 252 barcoded canonical and aberrant protein-coding transcripts induced by recurrent mutations in U2AF1, SF3B1, and SRSF2 which are predicted to be NMD-neutral. The pooled library was expressed in primary Tet2-deficient hematopoietic stem and progenitor cells (HSPCs), due to the frequent co-occurrence of TET2 and splicing factor mutations in myeloid neoplasms and transplanted into syngeneic recipients. Barcode abundance was quantified longitudinally across HSPCs and mature myeloid and B-cells.
The screen identified selective in vivo enrichment of isoforms converging on interferon signaling and MHC II antigen presentation machinery. Among the strongest hits was a U2AF1 mutation–induced isoform of SPPL2A, the protease required for cleavage of the MHC II invariant-chain chaperone CD74, a critical step for peptide loading and surface presentation of MHC II. Expression of this SPPL2A isoform in Tet2-deficient HSPCs drove progressive clonal expansion and fatal myeloid leukemia.
Structural modeling revealed that the mutant U2AF1-induced SPPL2A isoform lacks a loop that stabilizes CD74 engagement thereby impairing substrate cleavage. Consistent with this, SPPL2A loss or expression of the aberrant isoform caused accumulation of the CD74 N-terminal fragment in lysosomes, reducing cell-surface MHC II. Canonical SPPL2A restored CD74 proteolysis and MHC II expression in U2AF1-mutant cells, whereas the aberrant isoform did not. This defect disrupted CD4+ T-cell surveillance. Tet2-deficient HSPCs expressing aberrant SPPL2A failed to activate antigen-specific CD4+ T cells directed against MHC II presented peptides derived from the model antigen Ova. In a Tet2/Tp53 double-deficient AML model, aberrant SPPL2A impaired CD4+ T-cell–mediated leukemia clearance and shortened survival. In human tumor models, aberrant SPPL2A reduced killing of tumor cells by MHC II–restricted TCR-T cells directed against the cancer testis antigen MAGEA3, resulting in resistance to adoptive T-cell therapy in vivo.
In addition to SPPL2A mis-splicing, our in vivo cDNA screen also revealed that mutant U2AF1 simultaneously mis-splices CD74. This mutant isoform of CD74 contains a thyroglobulin-type 1 domain known to attenuate the activity of proteases. Consistent with this, this mutant isoform of CD74 further impaired MHC II peptide presentation and activity of TCR T cells directed against MAGEA3. Thus, mutant U2AF1 coordinately disables both the protease and substrate arms of the SPPL2A–CD74 antigen-processing pathway.
These findings establish a high-throughput in vivo framework for systematic functional interrogation of protein-coding RNA isoforms in clonal hematopoietic disorders. We identify coordinated mis-splicing of SPPL2A and CD74 as a previously unrecognized mechanism linking spliceosome mutations to mutant HSPC expansion, defective MHC II antigen presentation, and escape from CD4+ T-cell immune surveillance. Our results reveal RNA isoform regulation as a determinant of clonal fitness and antitumor immunity in clonal hematopoietic disorders and suggest that restoring antigen processing or correcting pathogenic splicing may restrain disease progression and enhance CD4+ T cell-directed immunotherapy.
DISCLOSURES
Pu Zhang: No relevant conflicts of interest to declare.